首页/数据集/The mean difference of ADAS-cog score according to the pharmaceutical augmentation.

The mean difference of ADAS-cog score according to the pharmaceutical augmentation.

Figshare2020-02-07 更新2026-04-28 收录

数据链接：

https://figshare.com/articles/dataset/The_mean_difference_of_ADAS-cog_score_according_to_the_pharmaceutical_augmentation_/11824050 数据链接链接失效反馈

官方服务：

资源简介：

The mean difference of ADAS-cog score according to the pharmaceutical augmentation.

应用场景：

创建时间：

2020-02-07

相关数据集

人工分子伴侣靶向神经细胞的实验数据

阿尔茨海默病治疗

纳米药物递送

此数据集包含了我们合成的两种不同的嵌段共聚物：RVG29-聚乙二醇-b-聚环己内酯（RVG29-PEG-b-PCL）和具有pH响应性的聚环己内酯-b-聚β-氨酯（PCL-b-PAE）与γ分泌酶抑制剂DAPT通过自组装制备得到以PCL为核，RVG29-PEG和PAE为混合壳层的复合胶束，通过调节环境pH至人体的正常生理pH（7.4），得到模拟分子伴侣结构的纳米胶束。该人工分子伴侣粒径大小在100nm

国家人口健康科学数据中心40

Intranasal triptolide in mice: a strategy to reduce neuroinflammation and boost cognitive function

阿尔茨海默病治疗

药物递送设备

This study developed triptolide-loaded liposomes (TPL) for intranasal delivery to mitigate systemic toxicity of free triptolide (TP) while enhancing therapeutic efficacy in neuroinflammatory and Alzhe

NIAID Data Ecosystem20

LMP2 Inhibitors as a Potential Treatment for Alzheimer’s Disease

阿尔茨海默病治疗

LMP2抑制剂开发

The immunoproteasome (iP), an inducible proteasome variant harboring three immunosubunits, low molecular mass polypeptide-2 (LMP2), multicatalytic endopeptidase complex subunit-1, and low molecular ma

NIAID Data Ecosystem10

orignal data.xlsx

阿尔茨海默病治疗

中药药理机制

Alzheimer's Disease (AD) is a neurodegenerative disorder characterized by cognitive impairment and memory decline. Ferroptosis is a form of cell death related to iron metabolism dysregulation that is

Figshare2025-04-28 更新30

Structure–Activity Relationships of Benzimidazole-Based Glutaminyl Cyclase Inhibitors Featuring a Heteroaryl Scaffold

药物分子设计

阿尔茨海默病治疗

Glutaminyl cyclase (hQC) has emerged as a new potential target for the treatment of Alzheimer’s disease (AD). The inhibition of hQC prevents of the formation of the Aβ3(pE)‑40,42 species which were sh

Figshare2016-02-18 更新20